Mark Roschewski
@RoschewskiMD
Followers
1K
Following
491
Media
64
Statuses
487
Lymphoma research during day (and many nights) // Royals and ND fan at night (and some days). Views are my own and not those of the NCI.
Bethesda, MD
Joined May 2012
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology https://t.co/jmQh4QsR3n Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.
ascopubs.org
PURPOSELarge B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA)...
8
23
70
#ESHLYMPHOID2025 REGISTRATION AND ABSTRACT SUBMISSION ARE OPEN ➡ https://t.co/WufaY2HYL8 Oct 2-4, 2025 in Estoril, Portugal 🇵🇹 8th Translational Research Conference LYMPHOID MALIGNANCIES Chairs: @HallekMichael, Georg Lenz, @SehnLaurie, @LouisStaudt, Catherine Wu #ESHCONFERENCES
0
6
21
Helpful review on ctDNA in lymphoma from @RoschewskiMD et al just out in @JAMAOnc
@dgermain21 @AshAlizadeh #lymsm #lymphoma @hjcherng @JAMA_current @JAMANetwork
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas. https://t.co/0ceKRDKfHY
5
10
52
The @NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment. @RoschewskiMD @AshAlizadeh @StanfordCancer #lymsm #hematology
https://t.co/aOcRURsXAL
onclive.com
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
0
4
13
Great news! I predict the tip of the iceberg for these tests. https://t.co/mBNXEk6Bay
foresight-dx.com
Boulder, CO — January 10, 2025 — Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the ...
1
2
9
"Step-down" trials have historically been more successful than "step-up" trials. We likely do not need 6 cycles for low-risk LBCL. Kudos to investigators
We are pleased to share that our Foresight CLARITY #MRD test will be used in @ColumbiaMed's SHORTEN-ctDNA trial, which aims to evaluate the ability to utilize MRD detection to enable real-time treatment optimization for patients with #DLBCL. https://t.co/jAEW8LJ54q
3
0
12
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS https://t.co/Q9N9Ccd0lz Read the background story of how the VIPOR drugs were discovered to have synergy in LBCL.
pnas.org
Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and well-validated drug activity in relevant disease mod...
0
3
7
ViPOR regimen in MCL #ASH24 @MelanicjMD: - 36 pts (16 R/R), 32% TP53mut, med LOT 3 - R2PD ven dose 400 mg, no TLS, 89% completed all 6 cycles - CR 100% (!!!) - 2-yr PFS: 1L 95%; R/R 75%; 2-yr TTP 100% in TP53mut Also uMRD in 97%! Looking forward to more details on TP53mut. #lymsm
0
8
25
Please join me for @KarmanosCancerInstitute’s Sixth Annual Lymphoma Symposium on Aug. 3 at Detroit Marriott Troy. I will be presenting on Primary CNS Lymphoma. Register online by Aug. 1 by visiting
0
0
3
Work from the Lymphoid Malignancies Branch reveals that ARID1A and SWI/SNF activity are required for IRF4-dependent transcription. Inhibition of SWI/SNF blocks plasma cell development and is toxic to myeloma cells. https://t.co/ADYhZp0A15
0
0
5
New work from the Lymphoid Malignancies Branch shows that loss of Ga13 drives B cell lymphomas preferentially in the mesenteric lymph nodes. Ga13 is required to counteract mTORC1 and Myc signaling that is driven by the availability of dietary glutamine. https://t.co/wQtc5FLwGU
0
0
4
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma | New England Journal of Medicine https://t.co/bdrUQJCWTQ Concept by Wyndham Wilson, pre-clinical rationale by Lou Staudt, and study led by @MelanicjMD . Thanks to all patients.
nejm.org
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple surviv...
6
12
72
BTK is known for its role in BCR signaling & BTKi transformed the therapy of lymphoid malignancies. But why do BTKi cause fungal disease? We show that BTK drives neutrophil antifungal activity via p40phox and RAC2 activation; GMCSF rescues BTKi PMN defects https://t.co/q3olu7NUvd
5
16
76
"@RoschewskiMD and his colleagues at the NCI speculated that a determination of MRD via ...PhasED-seq could provide a more reliable and complementary method for identifying the lymphoma patients that don't need further salvage therapy." #ASH23 @GenomeWeb
genomeweb.com
Researchers concluded based on data shared at ASH that ctDNA testing can accurately predict who can forgo salvage therapy and may limit the number of tests.
0
1
10
Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature. #lymsm 1/15 https://t.co/FOBvWSu5Je PDF link at bottom of this thread
nature.com
Nature - The potential use of circulating tumour DNA in classic Hodgkin lymphoma detection, classification and monitoring is defined.
20
79
219
Recommended reading: REVIEW ARTICLES Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy @DanielHodson20 @RoschewskiMD
@Haematologica #SCNSL Early View | Haematologica
0
5
33
#ctDNA may soon be effectively used to improve upon imaging scans to detect active large cell lymphoma at the end of treatment. #SOHO23 #lymsm | @RoschewskiMD @theNCI READ MORE:
targetedonc.com
Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.
0
1
2
PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL @RoschewskiMD @theNCI @SocietyofHemOnc #SOHO2023 #hematology
onclive.com
Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease...
0
4
6
To conclude, the effect of DLBCL cell of origin on polatuzumab efficacy was established by prior studies, & confirmed by 2 RCTs. Should this now inform precision medicine in DLBCL? 12/EOT. #lymsm @lymphoma @LLSusa @lymphomahub @DrAEvens @dgermain21 @MaurerStats @RoschewskiMD
4
2
20